Ertapenem Once a Day Versus Piperacillin–Tazobactam Every6 Hours for Treatment of Acute Pelvic Infections:A Prospective, Multicenter, Randomized, Double‐Blind Study
Authors:
Open Access
- 14 October 2002
- journal article
- clinical trial
- Published by Wiley in Infectious Diseases in Obstetrics and Gynecology
- Vol. 11 (1) , 27-37
Abstract
Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute pelvic infections.Methods: In a multicenter, double‐blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin–tazobactam, 3.375 g every 6 hours, both administered intravenously.Results: In total, 163 patients in the ertapenem group and 153 patients in the piperacillin–tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug‐related adverse events were generally similar in both groups.Conclusions: In this study, ertapenem was as effective as piperacillin–tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin–tazobactam.Keywords
Funding Information
- Merck
This publication has 10 references indexed in Scilit:
- In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and AustraliaAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Activities of Ertapenem (MK-0826) against Clinical Bacterial Isolates from 11 North American Medical CentersAntimicrobial Agents and Chemotherapy, 2001
- The epidemiology of missed medication doses in hospitalized patients.1996
- Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group.1994
- Evaluation of New Anti-Infective Drugs for the Treatment of Acute Pelvic Infections in Hospitalized WomenClinical Infectious Diseases, 1992
- Evaluating the Cost Impact of Intravenous Antibiotic Dosing FrequenciesDICP, 1991
- Antibiotic usage in pelvic infections. An overview.1988
- Multicenter comparison of cefotetan and cefoxitin in the treatment of acute obstetric and gynecologic infectionsAmerican Journal of Obstetrics and Gynecology, 1988
- Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infectionsAmerican Journal of Obstetrics and Gynecology, 1987
- “Proving the null hypothesis” in clinical trialsControlled Clinical Trials, 1982